Volume 78, Issue 5, Pages (September 2010)

Slides:



Advertisements
Similar presentations
Evaluation and treatment of coronary artery disease in patients with end-stage renal disease Peter A. McCullough Kidney International Volume 67, Pages.
Advertisements

Vitamin D levels and patient outcome in chronic kidney disease
Beta blockers in the management of chronic kidney disease
Urinary ammonia and long-term outcomes in chronic kidney disease
Volume 83, Issue 3, Pages (March 2013)
Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure  Steven Fishbane, Nobuyuki Miyawaki  Kidney International 
Long-term follow-up of patients randomized to biocompatible or conventional peritoneal dialysis solutions show no difference in peritonitis or technique.
C-reactive protein and dialysis access
Rajiv Agarwal, John W. Kusek, Maria K. Pappas  Kidney International 
The risk of hospitalization and modality failure with home dialysis
C-reactive protein and dialysis access
Fluid overload and residual renal function in peritoneal dialysis: the proof of the pudding is in the eating  Wim Van Biesen, Achim Jörres  Kidney International 
Need for better diabetes treatment for improved renal outcome
Steroid-free maintenance immunosuppression in kidney transplantation: is it time to consider it as a standard therapy?  Fu L. Luan, Diane E. Steffick,
Volume 86, Issue 6, Pages (December 2014)
Volume 78, Issue 6, Pages (September 2010)
Steven G. Coca, Swathi Singanamala, Chirag R. Parikh 
Volume 80, Issue 9, Pages (November 2011)
Comorbidity and confounding in end-stage renal disease
Volume 82, Issue 3, Pages (August 2012)
Volume 77, Issue 2, Pages (January 2010)
Long-term study of mycophenolate mofetil treatment in IgA nephropathy
Volume 79, Issue 9, Pages (May 2011)
Correction to "Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate.
U-shaped effect of eGFR and mortality
The analysis of survival data: the Kaplan–Meier method
The calcium–phosphorus in guidelines for CKD-MBD
Prospective randomized study of individual and group psychotherapy versus controls in recipients of renal transplants1  Lyndsay S. Baines, John T. Joseph,
Volume 65, Issue 6, Pages (June 2004)
Nephrology Crossword: History of nephrology
Volume 76, Issue 5, Pages (September 2009)
Volume 81, Issue 6, Pages (March 2012)
Response to ‘Hepcidin levels in patients with renal disease’
Volume 68, Issue 6, Pages (December 2005)
Volume 76, Issue 6, Pages (September 2009)
Volume 87, Issue 1, Pages (January 2015)
Vitamin D levels and patient outcome in chronic kidney disease
Volume 82, Issue 10, Pages (November 2012)
Volume 69, Issue 12, Pages (June 2006)
Volume 69, Issue 3, Pages (February 2006)
Tilman B. Drüeke, Ziad A. Massy  Kidney International 
Volume 85, Issue 5, Pages (May 2014)
Alternate-day dialysis may be needed for hemodialysis patients
Volume 71, Issue 6, Pages (March 2007)
Volume 84, Issue 5, Pages (November 2013)
Nephrology Crossword: Glomerulonephritis
Lynda Anne Szczech, Ira L. Lazar  Kidney International 
Volume 74, Issue 5, Pages (September 2008)
Volume 71, Issue 12, Pages (June 2007)
A man with a hole in his penis
Volume 73, Issue 9, Pages (May 2008)
Volume 77, Issue 12, Pages (June 2010)
Volume 57, Issue 1, Pages (January 2000)
Volume 74, Issue 8, Pages (October 2008)
Racial differences in survival of patients on dialysis
Carmine Zoccali, Francesca Mallamaci  Kidney International 
Volume 70, Issue 7, Pages (October 2006)
Volume 80, Issue 10, Pages (November 2011)
Michael R. Lattanzio, Matthew R. Weir  Kidney International 
Charles A. Herzog  Kidney International 
Volume 75, Issue 1, Pages (January 2009)
Volume 83, Issue 3, Pages (March 2013)
Volume 87, Issue 3, Pages (March 2015)
Volume 70, Issue 5, Pages (September 2006)
Volume 82, Issue 9, Pages (November 2012)
Adiponectin: good, bad, or just plain ugly?
Survival of propensity matched incident peritoneal and hemodialysis patients in a United States health care system  Victoria A. Kumar, Margo A. Sidell,
E.F. Vonesh, J.J. Snyder, R.N. Foley, A.J. Collins 
Yoshitsugu Kaku, Kaoru Nohara, Sunao Honda  Kidney International 
Volume 77, Issue 2, Pages (January 2010)
Presentation transcript:

Volume 78, Issue 5, Pages 495-502 (September 2010) Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch Schönlein Purpura  Evangéline Pillebout, Corinne Alberti, Loic Guillevin, Amel Ouslimani, Eric Thervet  Kidney International  Volume 78, Issue 5, Pages 495-502 (September 2010) DOI: 10.1038/ki.2010.150 Copyright © 2010 International Society of Nephrology Terms and Conditions

Figure 1 Patient disposition. All patients received the allocated treatment. Patients shown as ‘not evaluated’ did not attend the relevant study visit. The last follow-up took place at a median of 61 months in the CS group and at 60 months in the CS+CYC group. Kidney International 2010 78, 495-502DOI: (10.1038/ki.2010.150) Copyright © 2010 International Society of Nephrology Terms and Conditions

Figure 2 Renal outcome. (a) eGFR (Cockcroft–Gault) and (b) daily proteinuria (g/day) in patients receiving steroids alone (CS, open boxes) or steroids and cyclophosphamide (CS+CYC, filled boxes) from day 0 (D0) until the last follow-up (LF). Kidney International 2010 78, 495-502DOI: (10.1038/ki.2010.150) Copyright © 2010 International Society of Nephrology Terms and Conditions

Figure 3 Kaplan–Meier curves comparing patients receiving steroids alone (CS) or associated with cyclophosphamide (CS+CYC): survival from randomization to the end of follow-up. Adjusted to treatment arm by multivariable analysis, BVAS at inclusion was the only parameter to show a statistically significant relationship with patient survival (hazards ratio, 2.4 for an increase of 10 BVAS points, 95% CI 1.4–4.5; P=0.003). Kidney International 2010 78, 495-502DOI: (10.1038/ki.2010.150) Copyright © 2010 International Society of Nephrology Terms and Conditions

Figure 4 Study design. All patients received intravenous methylprednisolone for 3 days, followed by oral prednisone. The patients were randomly assigned to receive, in addition to steroids, six pulses of intravenous cyclophosphamide. Kidney International 2010 78, 495-502DOI: (10.1038/ki.2010.150) Copyright © 2010 International Society of Nephrology Terms and Conditions